Lexicon Pharma (LXRX) Income Statement

Click line-items for a historical chart and %

Collaborative research	27.69M
Subscription and license fees	31K
Total revenues	27.72M
Research and development, including stock-based compensation of $818, $809, $1,657 and $1,615, respectively	52.53M
Increase in fair value of Symphony Icon, Inc. purchase liability	-2.15M
General and administrative, including stock-based compensation of $632, $511, $1,265 and $1,010, respectively	12.26M
Total operating expenses	62.65M
Loss from operations	-34.93M
Gain on investments, net
Interest income
Interest expense	-1.65M
Other income (expense), net	564K
Consolidated net loss	-36.02M
Consolidated net loss per common share, basic and diluted	-0.35
Shares used in computing consolidated net loss per common share, basic and diluted

Entities mentioned with LXRX

View All Entities